Navigation Links
Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
Date:9/29/2013

implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab, crolibulin or AmiKet™ will not be successful; the risk that bertilimumab, crolibulin, AmiKet™ or compounds arising from our NanomAb® program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at
SOURCE Immune Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Increasing Public Health Awareness Intensifies Global Uptake of Autoimmune Disease Diagnostics
2. Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform
3. Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013
4. Immune Pharmaceuticals Completes Merger with EpiCept Corporation
5. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
6. EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.
7. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
8. aTyr Pharma Completes $49 Million Financing to Advance a Therapeutic Pipeline for Rare Autoimmune Diseases from a Newly Discovered Class of Proteins, Physiocrines
9. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
10. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
11. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food and ... for the prevention of serogroup B meningococcal disease ... Pfizer,s vaccine Trumenba®, which received FDA approval in October, ... devastating disease. "I have heard over ...
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
(Date:1/23/2015)... NEW YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer ... the board of directors of Advaxis, Inc. ("Advaxis" or ... the board has breached its fiduciary duties to shareholders. ... published on an investing website reporting that Advaxis had ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... BioCryst Says Study Confirms and Extends Evidence Seen ... /PRNewswire-FirstCall/ --,BioCryst Pharmaceuticals, Inc. today announced that investigators,at ... results evaluating peramivir treatment in an animal model,of ... virus (an avian,influenza strain that had caused fatal ...
... data show efficacy across the range of migraine ... many migraine,sufferers experience traditional symptoms such as nausea ... also involve,symptoms like neck pain or sinus pain ... data show that,significantly more patients using the investigational ...
Cached Medicine Technology:St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 2St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 3St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 4St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 5St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection 6Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 2Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 3Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 4Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 5
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... The Health Ethics Trust, a Division of the Council ... Compliance program an unconditional three-year certification effective October 5, ... month intensive review of the NHS program which included ... of highly respected compliance experts from around the country ...
... Hamilton, ON (Oct. 14, 2009) When people travel, bacteria ... billion people cross international borders each year, many more billions ... However, the trend is contributing to substantial domestic and international ... more recently with the H1N1 flu virus. In a ...
... prevent fever at shot time could be counterproductive, researchers say ... vaccination is a normal and essential part of building ... in the U.S. as Tylenol -- after a shot could ... vaccines, transient fever means that a child,s immune system is ...
... ... Suzanne Somers’ new book. , ... Potomac, MD (PRWEB) October 15, 2009 — Julian Whitaker, MD, has the distinct honor ... Curing Cancer and How to Prevent Getting It In the First Place. The book highlights ...
... Inc., today announced that Grant Asay has been promoted ... specialty acute care hospital system. As executive vice president ... quality of care and governance of all LifeCare hospitals. ... with more than 22 years experience. He joined LifeCare ...
... HARBIN, China, Oct. 15 /PRNewswire-Asia-FirstCall/-- SOKO Fitness ... today reported the,operating results for the first quarter of ... revenue grew 50% to $6.43 million from $4.28 million ... first quarter grew 68% to $2.43,million and fully diluted ...
Cached Medicine News:Health News:Paradigm shift needed to combat drug resistance 2Health News:Acetaminophen May Weaken Effectiveness of Kids' Vaccines 2Health News:Dr. Julian Whitaker Pens Forward for Suzanne Somers' New Cancer Book 2Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 2Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 3Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 4Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 5Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 6Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 7
... Growth Stimulator is a portable, battery-powered bone growth ... fusion. The device is worn for 30 minutes ... to the fusion site. The device uses a ... very low energy signal that is very potent ...
... Frontier device is a multi-site, ... one atrial and two ventricular ... atrial fibrillation (AF) who have ... and who have NYHA Class ...
Intrinsic Dual Chamber ICD With MVP Mode (Managed Ventricular Pacing). MVP promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular (RV) pacing to approximately...
... to 8 Fr. access sites following diagnostic or ... System is indicated for the percutaneous delivery of ... site of patients who have undergone diagnostic or ... The Closer S 6F SMC System reduces the ...
Medicine Products: